GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...
News Medical on MSN4h
GLP-1, SGLT2 Drugs Cut Heart Risk for Stroke SurvivorsIn an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...
Both are risk factors for heart attack and stroke. “Another mechanism that could be very important for this current study is ...
Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...
Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.
GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial ...
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial Officer ...
The study confirmed that the degree of weight loss was independently associated with the improvement of all NASH-related histological parameters (OR 1.1 - 2.0; P < 0.01). Among patients with weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback